Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
Date:8/16/2010

nt, providing more time for a donor organ to become available. In May 2010, the FDA accepted the sNDA and granted a priority review. In addition to expanded labeling, the Company has requested additional exclusivity for the product and, if approved, expects to begin marketing it with the new indication in 2011.

International MarketsAcetadote Approved for Marketing in Australia

Cumberland has granted an exclusive license to Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, to commercialize Acetadote in Australia. In April 2010, the Therapeutics Goods Administration (TGA), which regulates drugs and medical devices in Australia, approved Acetadote for marketing. Phebra is preparing for the Australian launch of the product, which it expects to commence this year. Under the agreement, Phebra is responsible for ongoing regulatory requirements, marketing, distribution and sales of Acetadote in Australia, New Zealand and the Asia Pacific while Cumberland maintains responsibility for product formulation, development and manufacturing. Cumberland receives milestone payments and royalties on future sales in exchange for the product license.

Caldolor Launched for Compassionate Use in Australia

In 2009, Cumberland entered into an exclusive agreement with Phebra Pty Ltd. for distribution of Caldolor in Australia and New Zealand. The Therapeutics Goods Administration operates compassionate use programs allowing patients with critical clinical needs to access products not yet approved. In April 2010, Phebra made Caldolor available in Australia for compassionate use.

Submission of New Drug Application for Caldolor in South Korea

In December 2009, Cumberland entered into an exclusive agreement with DB Pharm Korea Co. Ltd., a Korean-based pharmaceutical company, for the commercialization of Caldolor in South Korea. Under the terms of the agreement DB Pharm Korea is responsible for seeking regu
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
4. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
5. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... March 3, 2011 Palatin Technologies, Inc. (NYSE Amex: ... Drug Administration (FDA) has cleared Palatin,s request to begin a ... (IND) application using a subcutaneously administered formulation of PL-3994, an ... of asthma. "We are excited about the ...
... 3, 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... the FDA,s Office of New Drugs ("OND") in Maryland and ... contained in its New Drug Application ("NDA") 22-481 support the ... "We appreciate OND,s consideration of our appeal.  While we ...
Cached Medicine Technology:FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 2FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 3
(Date:7/10/2014)... the clinical indicators most strongly associated with concussion is ... evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according ... , official journal of the Congress ... Lippincott Williams & Wilkins , a part of ... on analysis of the best available research data, a ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
(Date:7/9/2014)... If you think winning is one of the key determinants ... along with other mental bonuses ranked near the bottom of ... of 11 big fun factors, according to a new study. ... it comes to the "fun" factor, very little research had ... this elusive conceptuntil now. , The results of this study ...
(Date:7/9/2014)... associated with a small increased risk of prostate cancer, ... cancer according to a new study from Harvard School ... association remained even among men who received regular PSA ... be explained by diagnostic bias. It is the largest ... the link between vasectomy and prostate cancer. , The ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
Breaking Medicine News(10 mins):Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... of his work,to ensure that all Pennsylvanians have access ... said 35,000 uninsured,individuals who have been waiting to enroll ... to receive health coverage at a,monthly premium of $33.50., ... and peace of mind,that every Pennsylvanian deserves," said Governor ...
... 40% of patients stopped taking drugs in Italian study , , ... taking cholesterol-lowering statins doubled their risk of dying in the ... an Italian study finds. , A number of other studies ... the study authors noted. , For instance, the Italian study ...
... cord dysfunction (VCD) is the sudden, abnormal narrowing of the ... is characterized by a noise that can mimic the sound ... an asthma attack though it does not respond to asthma ... the disorder using breathing and relaxation techniques to help the ...
... than visually inspecting the disease, doctors have no genetic blueprint ... Tumors generally are ranked by how deeply the growth has ... the skin, the more lethal the cancer, but some patients ... from thin ones. Two melanoma patients with cancers of ...
... Disease Control report that nearly 25 million women are infected with ... more than three million are thought to have one of the ... warts. , HPV is linked to oropharyngeal cancer and may be ... developed to treat HPV might decrease the risk of these cancers, ...
... group suggests , THURSDAY, Aug. 30 (HealthDay News) -- ... suffer oral allergy syndrome (OAS), which results from a ... and trees and similar proteins in some fresh fruits ... known as pollen-food syndrome -- include: itchiness, tingling or ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Stopping Statins After Stroke Doubles Death Risk 2Health News:Stopping Statins After Stroke Doubles Death Risk 3Health News:Study finds some kids are being misdiagnosed with asthma 2Health News:Gene signature spells poor outcome 2Health News:Human Papilloma Virus vaccines may decrease chances of oral cancer 2Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... an affordable path to Sonesta flexibility. ... and back adjustments. Packaged with basic ... line of Sonesta add-ons, allowing you ... your needs; complete Sonesta flexibility at ...
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... The BiliChek measures total serum bilirubin ... no risk of infection compared to the ... Using light, BiliChek tests bilirubin levels without ... Only the replaceable plastic tip touches the ...
Medicine Products: